New PET tracer detects lung tumors
An experimental PET radiotracer is safe and appears effective for detectin...Read more on AuntMinnie.comRelated Reading: PET tracer proves effective for assessing immunotherapy Quitting smoking slows early lung cancer progression CT identifies candidates for sublobar resection for lung cancer CT radiomics predicts survival in NSCLC patients Falling lung cancer rates drive cancer decline in U.S. (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 3, 2021 Category: Radiology Source Type: news

KRAS Mutation Predicts Pembrolizumab Response in NSCLC KRAS Mutation Predicts Pembrolizumab Response in NSCLC
A new study, published as a preprint, reported a better way to predict if patients with metastatic nonsmall cell lung cancer will respond to pembrolizumab.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Can Aspirin Prolong Survival in Patients With NSCLC? Can Aspirin Prolong Survival in Patients With NSCLC?
A new study shows that people with inoperable non-small cell lung cancer who took the cheap painkiller survived longer, but questions linger.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

The Roles and Therapeutic Potential of Clusterin in NSCLC The Roles and Therapeutic Potential of Clusterin in NSCLC
A better understanding of the clinical relevance of clusterin in non-small cell lung cancer could lead to the development of more effective targeted therapies.Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 1, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Diagnosis and Treatment of Non-Small Cell Lung Cancer: From Where We Have Been to Where We Are Going Diagnosis and Treatment of Non-Small Cell Lung Cancer: From Where We Have Been to Where We Are Going
Sandip Patel, MD, describes a changing oncologic landscape in which treatment of non-small cell lung cancer (NSCLC) has given rise to new modes and values.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 29, 2021 Category: Consumer Health News Tags: None MDAngle Source Type: news

Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics
Adds LNG-451, a highly selective brain-penetrant precision therapy targeting EGFR exon 20 insertion mutations, to Blueprint Medicines' lung cancer pipeline Lengo Therapeutics on track to submit IND to FDA for LNG-451 by the end of 2021 Lengo Therapeu... Biopharmaceuticals, Oncology, Mergers & Acquisitions Blueprint Medicines, Lengo Therapeutics, precision therapy, NSCLC (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 29, 2021 Category: Pharmaceuticals Source Type: news

Treatment of Non-Small Cell Lung Cancer: Picking the Best Path Treatment of Non-Small Cell Lung Cancer: Picking the Best Path
Sandip Patel, MD, advises clinicians early in their careers that choosing exemplary care of patients with non-small cell lung cancer can be like finding the right path on a map.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 23, 2021 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news

Molecular Testing in mNSCLC: Digging a Little Deeper Makes All the Difference Molecular Testing in mNSCLC: Digging a Little Deeper Makes All the Difference
Dr Patel notes that in NSCLC,"we have to become increasingly sophisticated in our ability to interpret molecular information" and use next-generation sequencing to"dig a little deeper for certain patient scenarios."Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 22, 2021 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news

European Commission approves Roche ’s Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer
Basel, 19 November 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) has granted conditional marketing authorisation for Gavreto ® (pralsetinib) as a monotherapy for the treatment of adults with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor. Gavreto is the first and only precision medicine approved in the European Union (EU) for th e first-line treatment of people with RET fusion-positive advanced NSCLC.1 (Source: Roche Media News)
Source: Roche Media News - November 19, 2021 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer
Basel, 19 November 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) has granted conditional marketing authorisation for Gavreto ® (pralsetinib) as a monotherapy for the treatment of adults with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor. Gavreto is the first and only precision medicine approved in the European Union (EU) for th e first-line treatment of people with RET fusion-positive advanced NSCLC.1 (Source: Roche Investor Update)
Source: Roche Investor Update - November 19, 2021 Category: Pharmaceuticals Source Type: news

What Are the Stages and Survival Rates of NSCLC?
Title: What Are the Stages and Survival Rates of NSCLC?Category: Diseases and ConditionsCreated: 11/18/2021 12:00:00 AMLast Editorial Review: 11/18/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - November 18, 2021 Category: Cancer & Oncology Source Type: news

Treatment of Advanced Non-Small Cell Lung Cancer: From the Impossible to the Possible Treatment of Advanced Non-Small Cell Lung Cancer: From the Impossible to the Possible
How developments in the field of advanced non-small cell lung cancer have led Dr H. Jack West to"question whether what we thought was once impossible, is now possible."Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 17, 2021 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news

EU Panel Endorses First-of-Its-Kind Lung Cancer Drug EU Panel Endorses First-of-Its-Kind Lung Cancer Drug
Sotorasib is the first drug to successfully target KRAS mutations in non-small cell lung cancer.International Approvals (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - November 15, 2021 Category: Radiology Tags: Hematology-Oncology News Alert Source Type: news

PET tracer proves effective for assessing immunotherapy
PET imaging can show whether patients with melanoma or non-small cell lung cance...Read more on AuntMinnie.comRelated Reading: U.S. cancer care financial burden hit $21B in 2019 New PET radiotracer more effective at detecting cancer PET tracer predicts response to immunotherapy AI can lend a hand in diagnosis, prognosis of oral SCC PET/CT shows promise predicting outcomes in head, neck cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 3, 2021 Category: Radiology Source Type: news

EXKIVITY (mobocertinib), First and Only FDA Approved Oral Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer, Available at Biologics by McKesson
CARY, N.C., Nov. 3, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Takeda Pharmaceutical Limited Company as a specialty pharmacy provider for EXKIVITYTM (mobocertinib) for the treatment of adult patients with locally adv... (Source: McKesson News)
Source: McKesson News - November 3, 2021 Category: Information Technology Source Type: news

Lobectomy or Sub-Lobar Resection for Advanced-Stage NSCLC Lobectomy or Sub-Lobar Resection for Advanced-Stage NSCLC
Which of these two surgical options provide a greater survival benefit in metastatic non-small cell lung cancer?Translational Lung Cancer Research (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - November 1, 2021 Category: Surgery Tags: Hematology-Oncology Journal Article Source Type: news

Now Takeda Offers Rebate if Lung Cancer Drug Fails to Work Now Takeda Offers Rebate if Lung Cancer Drug Fails to Work
Following Pfizer's action with crizotinib, now Takeda is offering a rebate for brigatinib if it doesn't work. Both drugs are for ALK+ve non-small cell lung cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 27, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Roche ’s VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq® (atezolizumab)
Basel, 22 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA PD-L1 (SP263) Assay in non- small cell lung cancer (NSCLC) as a companion diagnostic test for Tecentriq, advancing the company's commitment to guide clinical decision making through innovative, high quality assays that improve patient access to personalized healthcare. (Source: Roche Media News)
Source: Roche Media News - October 22, 2021 Category: Pharmaceuticals Source Type: news

Roche ’s VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq® (atezolizumab)
Basel, 22 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA PD-L1 (SP263) Assay in non- small cell lung cancer (NSCLC) as a companion diagnostic test for Tecentriq, advancing the company's commitment to guide clinical decision making through innovative, high quality assays that improve patient access to personalized healthcare. (Source: Roche Investor Update)
Source: Roche Investor Update - October 22, 2021 Category: Pharmaceuticals Source Type: news

Lung cancer survival rates improve, thanks in part to earlier diagnosis, study finds
More than one in four people with non-small-cell lung cancer survive at least five years after their diagnosis, an analysis published Thursday by JAMA Oncology found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 21, 2021 Category: Consumer Health News Source Type: news

Johnson & Johnson Reports Q3 2021 Results
New Brunswick, N.J. (October 19, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2021. “Our third-quarter results demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in Pharmaceuticals, ongoing recovery in Medical Devices, and strong growth in Consumer Health,” said Alex Gorsky, Chairman and Chief Executive Officer. “In the face of evolving marketplace dynamics resulting from the effects of COVID-19 and other global trends, we have continued to demonstrate the responsiveness and agility required to meet the needs of ou...
Source: Johnson and Johnson - October 19, 2021 Category: Pharmaceuticals Tags: Financial Source Type: news

FDA OKs Adjuvant Atezolizumab for Early-Stage Lung Cancer FDA OKs Adjuvant Atezolizumab for Early-Stage Lung Cancer
The drug is now also approved for adjuvant treatment following resection and platinum-based chemotherapy in early stage, non-small cell lung cancer with PD-L1 ≥ 1%.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 15, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

US FDA approves Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 15 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq ® (atezolizumab) as adjuvant treatment, following surgery and platinum-based chemotherapy, for adults with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-approved test. (Source: Roche Media News)
Source: Roche Media News - October 15, 2021 Category: Pharmaceuticals Source Type: news

US FDA approves Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 15 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq ® (atezolizumab) as adjuvant treatment, following surgery and platinum-based chemotherapy, for adults with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-approved test. (Source: Roche Investor Update)
Source: Roche Investor Update - October 15, 2021 Category: Pharmaceuticals Source Type: news

FDA approves atezolizumab as adjuvant treatment for non-small cell lung cancer
Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 15, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

New Opdivo/Yervoy Mesothelioma Clinical Trial Begins Soon
A novel clinical trial involving the immunotherapy combination of Opdivo and Yervoy will open soon in Chicago. The goal is to study the drugs’ efficacy when added to surgery for patients with peritoneal mesothelioma cancer. The single-center, phase II clinical trial follows a recent report detailing the impressive three-year effectiveness of the drug combination when used for unresectable pleural mesothelioma. Bristol Myers Squibb manufactures Opdivo and Yervoy, known generically as nivolumab and ipilimumab. The U.S. Food and Drug Administration approved the combination for pleural mesothelioma in 2020, making ...
Source: Asbestos and Mesothelioma News - October 7, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Durvalumab cost effective in unresectable stage III NSCLC
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2021 Category: Drugs & Pharmacology Source Type: news

Once-Daily Poziotinib Shows Efficacy in NSCLC HER2 Exon 20 Once-Daily Poziotinib Shows Efficacy in NSCLC HER2 Exon 20
The drug showed clinically meaningful efficacy for patients with treatment-naive nonsmall cell lung cancer HER2 exon 20 mutations.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 29, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New Phase III data support the benefit of Roche ’s Tecentriq in early-stage lung cancer
Basel, 20 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented new data from the Phase III IMpower010 study at the European Society for Medical Oncology (ESMO) Congress 2021 Presidential Symposium, reinforcing the significant disease-free survival (DFS) benefit offered by Tecentriq ® (atezolizumab) for people with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%. Data from the IMpower010 trial were published simultaneously in The Lancet. In IMpower010, treatment with Tecentriq, following surgery and chemotherapy, reduced the risk of disease re currence or death (DFS) by ...
Source: Roche Media News - September 20, 2021 Category: Pharmaceuticals Source Type: news

New Phase III data support the benefit of Roche ’s Tecentriq in early-stage lung cancer
Basel, 20 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented new data from the Phase III IMpower010 study at the European Society for Medical Oncology (ESMO) Congress 2021 Presidential Symposium, reinforcing the significant disease-free survival (DFS) benefit offered by Tecentriq ® (atezolizumab) for people with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%. Data from the IMpower010 trial were published simultaneously in The Lancet. In IMpower010, treatment with Tecentriq, following surgery and chemotherapy, reduced the risk of disease re currence or death (DFS) by ...
Source: Roche Investor Update - September 20, 2021 Category: Pharmaceuticals Source Type: news

New Data on RYBREVANT ® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.[i] While previously reported results have demonstrated durable responses with RYBREVANT® in combination with...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

RYBREVANT ® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib.[1] The analysis showed higher activity and longer duration of response (DOR) in patients treated with the combination therapy, demonstrating the potential benefit of targeting the extracellular (outer) and catal...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Improved Survival in Patients With NSCLC and Brain Metastases Improved Survival in Patients With NSCLC and Brain Metastases
About a third of the patients with NSCLC and brain metastases treated with atezolizumab in combination with chemotherapy had overall survival improved to 2 years.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 17, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

' Urgent' Need to Understand Immunotherapy De-escalation in NSCLC'Urgent' Need to Understand Immunotherapy De-escalation in NSCLC
The strong and durable response to immunotherapy in some patients suggests treatment could be reduced or withdrawn, but questions surround which patients will be ideal candidates, an expert argues.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 17, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Roche receives positive CHMP opinion for Gavreto ® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer
Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Gavreto® (pralsetinib) as a monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated w ith a RET inhibitor. (Source: Roche Media News)
Source: Roche Media News - September 17, 2021 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Gavreto ® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer
Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Gavreto® (pralsetinib) as a monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated w ith a RET inhibitor. (Source: Roche Investor Update)
Source: Roche Investor Update - September 17, 2021 Category: Pharmaceuticals Source Type: news

Cell therapy partnership between Bay Area biotechs offers hope to cancer patients
Imagine a world in which physicians can confidently cure cancer. Two Bay Area life sciences companies are working together to make this vision a reality. Atara Biotherapeutics Inc., founded in 2012, is developing a pipeline of cell therapies to treat various types of cancer and autoimmune diseases. Bayer is licensing Atara’s cutting-edge cell therapies that t arget certain types of aggressive tumors including mesothelioma, pancreatic, ovarian and non-small-cell lung cancer. “With cancer therapies,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 16, 2021 Category: Pharmaceuticals Authors: Lauren Lawley Head Source Type: news

FDA Approves First Oral Drug for NSCLC With EGFR Exon20 Insertion FDA Approves First Oral Drug for NSCLC With EGFR Exon20 Insertion
The FDA has granted an accelerated approval to mobocertinib for the treatment of locally advanced or metastatic nonsmall cell lung cancer with a specific type of EGFR mutation.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 16, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA grants accelerated approval to mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations
Oncology (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 16, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Ramucirumab Shows Survival Benefits with Pleural Mesothelioma
Adding the drug ramucirumab to gemcitabine chemotherapy worked especially well in a recent clinical trial involving second-line treatment for patients with pleural mesothelioma. Ramucirumab, an immunotherapy drug also known by the brand name Cyramza, is a monoclonal antibody that works by targeting and restricting a protein that stimulates blood vessel growth within tumors. Impressive results in the phase II clinical trial moved the drug combination closer to filling the long-standing void for a second-line mesothelioma treatment. The Lancet Oncology recently published results of the study, which was conducted in ...
Source: Asbestos and Mesothelioma News - September 13, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Which Patients Benefit Most From Adjuvant Atezolizumab in NSCLC? Which Patients Benefit Most From Adjuvant Atezolizumab in NSCLC?
A new analysis of data from IMpower010 has sparked a debate over which patients with early non-small cell lug cancer benefit most.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 11, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate can...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Metformin Disappoints in Two Phase 2 Lung Cancer Trials Metformin Disappoints in Two Phase 2 Lung Cancer Trials
Although well tolerated, metformin did not improve survival when given alongside chemoradiotherapy to patients with locally advanced non-small cell lung cancer (NSCLC).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 3, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Liquid Biopsy in NSCLC -- Current Status and Future Outlook Liquid Biopsy in NSCLC -- Current Status and Future Outlook
In this review, the current role and possible future applications of liquid biopsy in the management of non-small cell lung cancer are explored.Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 2, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Authors Tackle ICI Use in Problematic Lung Cancer Patients Authors Tackle ICI Use in Problematic Lung Cancer Patients
To use or not to use immune checkpoint inhibitors in advanced NSCLC? Some tentative answers for problematic patients.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 27, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Janssen Presents Phase 1 Results for RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
August 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANTTM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. The initial data showed anti-tumor activity in patients with METex14 mutations and a safety profile consistent with reported experience at the approved CHRYSALIS Phase 2 dose (RYBREVANTTM 1050 mg [
Source: Johnson and Johnson - August 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Minimally Invasive Pneumonectomy Seems Safe, Effective for NSCLC Minimally Invasive Pneumonectomy Seems Safe, Effective for NSCLC
Uniportal video-assisted thoracoscopic surgery achieved similar morbidity and mortality rates to open pneumonectomy in patients with centrally located non-small cell lung cancer in a retrospective, propensity-scored study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - August 10, 2021 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Is Non-Small Cell Lung Cancer Aggressive
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - August 3, 2021 Category: General Medicine Source Type: news

US FDA grants Priority Review to Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-appro ved test. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and ef...
Source: Roche Media News - August 3, 2021 Category: Pharmaceuticals Source Type: news

US FDA grants Priority Review to Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-appro ved test. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and ef...
Source: Roche Investor Update - August 3, 2021 Category: Pharmaceuticals Source Type: news